普拉克索联合美多巴治疗帕金森病非运动症状疗效(1)
摘 要 目的：探讨普拉克索联合美多巴治疗帕金森病非运动症状的临床疗效。方法：收集2016年1月至2018年4月治疗的帕金森病非运动症状患者66例，分为观察组和对照组各33例。对照组给予美多巴0.125 g/次，3次/d；1周后日口服量加0.125 g，逐步累加，直至达到患者的合适剂量。观察组在对照组基础上，同时给予普拉克索0.125 mg/次，3次/d；然后每周增加1次剂量，直至0.5 mg/次。两组均治疗8周。观察两组治疗前后汉密尔顿抑郁量表(HAMD)、非运动症状(NMS)、帕金森病睡眠量表(PDSS)、简易精神量表(MMSE)和生活质量评分。结果：治疗后，观察组的HAMD和NMS评分低于治疗前[(7.12±2.15)分比(41.37±7.55)分，(12.47±2.03)分比(17.96±3.58)分，P<0.05]和对照组[(7.12±2.15)分比(16.82±7.46)分，(12.47±2.03)分比(15.35±3.33)分，P<0.05]；PDSS和MMSE评分高于治疗前[(113.15±15.34)分比(86.41±5.89)分，(26.84±5.16)分比(10.47±3.66)分]和对照组[(113.15±15.34)分比(100.27±10.49)分，(26.84±5.16)分比(20.05±5.26)分，P<0.05]。观察组治疗后生活质量评分高于治疗前和对照组(P<0.05)。结论：普拉克索联合美多巴治疗帕金森病非运动症状有积极效果，能够改善患者HAMD、NMS、PDSS和MMSE评分，提高患者的生活质量。
关键词 帕金森病；非运动症状；普拉克索；美多巴
中图分类号：R742.5 文献标志码：A 文章编號：1006-1533(2019)08-0018-03
Therapeutic effect of pramipexole combined with madopar in the treatment of nonmotor symptoms of Parkinson’s disease
LIU Xuming
(Department of Neurology of People’s Hospital of Shangrao County， Shangrao 334100， Jiangxi Province， China)
ABSTRACT Objective： To explore the clinical efficacy of pramipexole combined with madopar in the treatment of nonmotor symptoms of Parkinson’s disease. Methods： From January 2016 to April 2018， 66 patients with non-motor symptoms of Parkinson’s disease treated were collected and divided into an observation group with 33 cases and a control group with 33 cases. The control group was given madopar 0.125 g/time， 3 times a day； after 1 week， the oral dose was increased by 0.125 g， and gradually increased until the appropriate dose of the patient was reached. The observation group was given pramipexole 0.125 mg/time， 3 times a day on the basis of the control group； then the dose was increased once a week until 0.5 mg/time. Both groups were treated for 8 weeks. The Hamilton depression scale(HAMD)， non-motor symptoms(NMS)， Parkinson’s disease sleep scale(PDSS)， minimum mental state examination(MMSE)， and scores of life quality of the two groups were observed before and after treatment. Results： After treatment， the HAMD and NMS scores in the observation group were lower than those before treatment[(7.12±2.15) vs. (41.37±7.55)， (12.47±2.03) vs. (17.96±3.58)， P<0.05] and those in the control group[(7.12±2.15) vs. (16.82±7.46)， (12.47±2.03) vs. (15.35±3.33)， P<0.05]. The scores of PDSS and MMSE in the observation group were higher than those before treatment[(113.15±15.34) vs. (86.41±5.89)， (26.84±5.16) vs. (10.47±3.66)] and those in the control group[(113.15±15.34) vs. (100.27±10.49)， (26.84±5.16) vs. (20.05±5.26)， P<0.05]. The score of life quality in the observation group after treatment was higher than that before treatment and in the control group(P<0.05). Conclusion： Pramexex combined with madopar has a positive effect in the treatment of non-motor symptoms of Parkinson’s disease， which can improve patients’HAMD， NMS， PDSS， MMSE scores and improve their quality of life., 百拇医药(刘旭明)
关键词 帕金森病；非运动症状；普拉克索；美多巴
中图分类号：R742.5 文献标志码：A 文章编號：1006-1533(2019)08-0018-03
Therapeutic effect of pramipexole combined with madopar in the treatment of nonmotor symptoms of Parkinson’s disease
LIU Xuming
(Department of Neurology of People’s Hospital of Shangrao County， Shangrao 334100， Jiangxi Province， China)
ABSTRACT Objective： To explore the clinical efficacy of pramipexole combined with madopar in the treatment of nonmotor symptoms of Parkinson’s disease. Methods： From January 2016 to April 2018， 66 patients with non-motor symptoms of Parkinson’s disease treated were collected and divided into an observation group with 33 cases and a control group with 33 cases. The control group was given madopar 0.125 g/time， 3 times a day； after 1 week， the oral dose was increased by 0.125 g， and gradually increased until the appropriate dose of the patient was reached. The observation group was given pramipexole 0.125 mg/time， 3 times a day on the basis of the control group； then the dose was increased once a week until 0.5 mg/time. Both groups were treated for 8 weeks. The Hamilton depression scale(HAMD)， non-motor symptoms(NMS)， Parkinson’s disease sleep scale(PDSS)， minimum mental state examination(MMSE)， and scores of life quality of the two groups were observed before and after treatment. Results： After treatment， the HAMD and NMS scores in the observation group were lower than those before treatment[(7.12±2.15) vs. (41.37±7.55)， (12.47±2.03) vs. (17.96±3.58)， P<0.05] and those in the control group[(7.12±2.15) vs. (16.82±7.46)， (12.47±2.03) vs. (15.35±3.33)， P<0.05]. The scores of PDSS and MMSE in the observation group were higher than those before treatment[(113.15±15.34) vs. (86.41±5.89)， (26.84±5.16) vs. (10.47±3.66)] and those in the control group[(113.15±15.34) vs. (100.27±10.49)， (26.84±5.16) vs. (20.05±5.26)， P<0.05]. The score of life quality in the observation group after treatment was higher than that before treatment and in the control group(P<0.05). Conclusion： Pramexex combined with madopar has a positive effect in the treatment of non-motor symptoms of Parkinson’s disease， which can improve patients’HAMD， NMS， PDSS， MMSE scores and improve their quality of life., 百拇医药(刘旭明)